Pulmatrix Inc PULM
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-03-21 |
| Shares Out. | 3,650,000 |
| Website | pulmatrix.com/ ↗ |
| Phone | 13026365400 |
| Employees | 2 |
| Net Income | -$1.2M |
| Total Assets | $4.5M |
| Total Liabilities | $905,000 |
| Equity | $3.6M |
About Pulmatrix Inc
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
Pulmatrix Inc is a publicly traded company under the ticker symbol PULM on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2025-03-01)